<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02831998</url>
  </required_header>
  <id_info>
    <org_study_id>ZX-ZP-0073 / 865-105</org_study_id>
    <nct_id>NCT02831998</nct_id>
  </id_info>
  <brief_title>In-vivo Efficacy of Patient Preoperative Prep</brief_title>
  <official_title>Clinical Evaluation of the Antimicrobial Effectiveness of Topically Applied ZP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zurex Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zurex Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to demonstrate the antimicrobial efficacy of the ZP&#xD;
      Preoperative Prep on skin flora of the abdomen and inguinal regions of human subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 27, 2016</start_date>
  <completion_date type="Actual">April 9, 2017</completion_date>
  <primary_completion_date type="Actual">April 9, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bacterial Reduction</measure>
    <time_frame>10 minutes post product application</time_frame>
    <description>A 3-log10 CFU/cm^2 bacterial reduction on the inguinal region is considered a success.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bacterial Reduction - Abdomen</measure>
    <time_frame>10 minutes post product application</time_frame>
    <description>A 2-log10 CFU/cm^2 bacterial reduction on the abdomen region is considered a success.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">440</enrollment>
  <condition>Surgical Skin Preparation</condition>
  <arm_group>
    <arm_group_label>ZP (70% IPA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isopropyl alcohol (IPA) 70%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ChloraPrep</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZP Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ZP without IPA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZuraPrep</intervention_name>
    <description>Apply topically.</description>
    <arm_group_label>ZP (70% IPA)</arm_group_label>
    <other_name>Isopropyl alcohol 70%</other_name>
    <other_name>ZP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ChloraPrep</intervention_name>
    <description>Apply topically.</description>
    <arm_group_label>ChloraPrep</arm_group_label>
    <other_name>CHG 2%/IPA 70%</other_name>
    <other_name>Chlorhexidine gluconate 2% / Isopropyl alcohol 70%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZP Vehicle</intervention_name>
    <description>Apply topically.</description>
    <arm_group_label>ZP Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects of any race&#xD;
&#xD;
          -  Subjects in good health&#xD;
&#xD;
          -  Minimum skin flora baseline requirements on abdomen and groin&#xD;
&#xD;
          -  Skin free of tattoos, dermatoses, abrasions, cuts, lesions, or other skin disorder&#xD;
             near or on the applicable test area.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Topical or systemic antimicrobial exposure within 14 days prior to screening and&#xD;
             treatment days, including antibiotics.&#xD;
&#xD;
          -  Subjects with a history of skin sensitivity, skin allergies, or skin cancer.&#xD;
&#xD;
          -  Subjects who are pregnant, attempting pregnancy or nursing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MicroBioTest Laboratories</name>
      <address>
        <city>Sterling</city>
        <state>Virginia</state>
        <zip>20164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2016</study_first_posted>
  <results_first_submitted>May 7, 2021</results_first_submitted>
  <results_first_submitted_qc>July 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 19, 2021</results_first_posted>
  <disposition_first_submitted>July 20, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>July 20, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 24, 2018</disposition_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 11, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT02831998/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Enrollment consists of subjects that advanced from screening to randomization and treatment. Each subject had 2 test products applied bilaterally; therefore, the numbers will not add up uniformly across arms due to the pre-determined cohort/block design. Result totals will be less than than the treated number as the per subject/area/intervention anatomical site must have an acceptable baseline count/flora.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>ZP (Isopropyl alcohol (IPA) 70%) or CP or ZP Vehicle Applied topically to ab (for 30 seconds) or groin (for 2 minutes).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="440"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ZP</title>
              <participants_list>
                <participants group_id="P1" count="400"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>CP</title>
              <participants_list>
                <participants group_id="P1" count="400"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vehicle</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="440"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treated Population</title>
          <description>Each subject could have received 2 out of 3 test products randomly assigned. Demographics were not stratified by test product due to study design. While 440 was the treated population, to be evaluable for efficacy, each subject anatomical sample site (4/per subject) would need to pass the minimum log10 baseline requirements.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="440"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.4" lower_limit="18" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="379"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bacterial Reduction</title>
        <description>A 3-log10 CFU/cm^2 bacterial reduction on the inguinal region is considered a success.</description>
        <time_frame>10 minutes post product application</time_frame>
        <population>Treated subjects with a treatment day baseline criteria of 5.0-7.5 log10 CFU/cm^2 recoveries for each sampling site (2 groin sampling sites per subject).</population>
        <group_list>
          <group group_id="O1">
            <title>Mean Log Reduction - ZP (70% IPA) - Groin</title>
            <description>Isopropyl alcohol (IPA) 70%&#xD;
ZP: Apply topically.</description>
          </group>
          <group group_id="O2">
            <title>Mean Log Reduction - ChloraPrep - Groin</title>
            <description>Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%&#xD;
ChloraPrep: Apply topically.</description>
          </group>
          <group group_id="O3">
            <title>Mean Log Reduction - ZP Vehicle - Groin</title>
            <description>ZP without IPA&#xD;
ZP Vehicle: Apply topically.</description>
          </group>
        </group_list>
        <measure>
          <title>Bacterial Reduction</title>
          <description>A 3-log10 CFU/cm^2 bacterial reduction on the inguinal region is considered a success.</description>
          <population>Treated subjects with a treatment day baseline criteria of 5.0-7.5 log10 CFU/cm^2 recoveries for each sampling site (2 groin sampling sites per subject).</population>
          <units>log10 CFU/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="326"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" spread="0.1"/>
                    <measurement group_id="O2" value="4.78" spread="0.1"/>
                    <measurement group_id="O3" value="2.23" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Groin 10 minutes Average Treatment Effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 CFU/cm^2 bacterial counts and the predictors were the treatment effect as a fixed effect and the pre-treatment log10 CFU/cm^2 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Investigational product upper bounds must be less than 0.5.</non_inferiority_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0,052</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.188</ci_lower_limit>
            <ci_upper_limit>0.083</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Groin 10 minutes Average Treatment Effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 CFU/cm^2 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 CFU/cm^2 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Investigational product lower bounds must be greater than 1.2.</non_inferiority_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>2.627</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.396</ci_lower_limit>
            <ci_upper_limit>2.858</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bacterial Reduction - Abdomen</title>
        <description>A 2-log10 CFU/cm^2 bacterial reduction on the abdomen region is considered a success.</description>
        <time_frame>10 minutes post product application</time_frame>
        <population>Treated subjects with a treatment day baseline criteria of 3.0 - 5.5 Log10 CFU/cm^2 recoveries.</population>
        <group_list>
          <group group_id="O1">
            <title>Mean Log Reduction - ZP (70% IPA) - Abdomen</title>
            <description>Isopropyl alcohol (IPA) 70%&#xD;
ZP: Apply topically.</description>
          </group>
          <group group_id="O2">
            <title>Mean Log Reduction - ChloraPrep - Abdomen</title>
            <description>Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%&#xD;
ChloraPrep: Apply topically.</description>
          </group>
          <group group_id="O3">
            <title>Mean Log Reduction - ZP Vehicle - Abdomen</title>
            <description>ZP without IPA&#xD;
ZP Vehicle: Apply topically.</description>
          </group>
        </group_list>
        <measure>
          <title>Bacterial Reduction - Abdomen</title>
          <description>A 2-log10 CFU/cm^2 bacterial reduction on the abdomen region is considered a success.</description>
          <population>Treated subjects with a treatment day baseline criteria of 3.0 - 5.5 Log10 CFU/cm^2 recoveries.</population>
          <units>Log10 CFU/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="340"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" spread="0.1"/>
                    <measurement group_id="O2" value="3.34" spread="0.1"/>
                    <measurement group_id="O3" value="1.47" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Abdomen 10 minutes Average Treatment Effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 CFU/cm^2 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 CFU/cm^2 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Investigational product average treatment effect upper bounds cannot be more than 0.5.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.018</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.102</ci_lower_limit>
            <ci_upper_limit>0.065</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Abdomen 10 minutes Average Treatment Effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 CFU/cm^2 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 CFU/cm^2 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Investigational product lower bounds must be greater than 1.2.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.909</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.766</ci_lower_limit>
            <ci_upper_limit>2.053</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 hours post product application</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ZP (70% IPA)</title>
          <description>Isopropyl alcohol (IPA) 70%&#xD;
ZP: Apply topically.</description>
        </group>
        <group group_id="E2">
          <title>ChloraPrep</title>
          <description>Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%&#xD;
ChloraPrep: Apply topically.</description>
        </group>
        <group group_id="E3">
          <title>ZP Vehicle</title>
          <description>ZP without IPA&#xD;
ZP Vehicle: Apply topically.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Morgan</name_or_title>
      <organization>Zurex Pharma, Inc.</organization>
      <phone>16082039090</phone>
      <email>amorgan@zurexpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

